Associated Papers
Association of UGT1A6 gene polymorphisms with sodium valproate-induced tremor in patients with epilepsy.
Yin Z et al.
Seizure, 2024
Mapping and annotating genomic loci to prioritize genes and implicate distinct polygenic adaptations for skin color.
Kim B et al.
Nature Communications, 2024
Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical Applications.
Gambari R et al.
International Journal of Molecular Sciences, 2024
Novel NARS2 variants in a patient with early-onset status epilepticus: case study and literature review.
Yang N et al.
Bmc Pediatrics, 2024
Evolutionary history of adenomas to colorectal cancer in FAP families.
Yang C et al.
Frontiers in Genetics, 2024
High throughput single cell long-read sequencing analyses of same-cell genotypes and phenotypes in human tumors.
Shiau CK et al.
Nature Communications, 2023
Impact of genetic polymorphisms on the risk of epilepsy amongst patients with acute brain injury: A systematic review.
Misra S et al.
European Journal of Neurology, 2023
Effects of UGT1A, CYP2C9/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients.
Zheng XX et al.
Pharmacogenomics, 2023
Genetic susceptibility of bladder cancer in the Lebanese population.
Kourie HR et al.
Bmc Medical Genomics, 2022
Impact of MDR1 and UGT Gene Polymorphisms on Sodium Valproate Plasma Concentration in Patients with Epilepsy.
Song C et al.
Clinical Laboratory, 2022
Common UGT1A6 Variant Alleles Determine Acetaminophen Pharmacokinetics in Man.
Cerezo-Arias MLO et al.
Journal of Personalized Medicine, 2022
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
Naagaard MD et al.
British Journal of Clinical Pharmacology, 2022
UGT1A6 and UGT2B7 Gene Polymorphism and its Effect in Pediatric Epileptic Patients on Sodium Valproate Monotherapy.
Nandith PB et al.
Indian Journal of Pediatrics, 2021
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.
Iannaccone T et al.
Pharmaceuticals (basel, Switzerland), 2021
Prioritization of candidate genes for a South African family with Parkinson's disease using in-silico tools.
Sebate B et al.
Plos One, 2021
Association of UGT1A6 gene polymorphism with clinical outcome in pediatric epileptic patients on sodium valproate monotherapy.
Banawalikar N et al.
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologica, 2021
Impact of Age and Genotype on Serum Concentrations of Valproic Acid and Its Hepatotoxic Metabolites in Chinese Pediatric Patients With Epilepsy.
Zhao M et al.
Therapeutic Drug Monitoring, 2020
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia.
Cacabelos R
International Journal of Molecular Sciences, 2020
Clinical Relevance of Pharmacogenetics in Serotonin Syndrome.
Pandya D et al.
Case Reports in Psychiatry, 2020
Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors.
Xu S et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences, 2018
Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
Chen G et al.
International Journal of Immunopathology and Pharmacology, 2017
Early post-traumatic seizures are associated with valproic acid plasma concentrations and UGT1A6/CYP2C9 genetic polymorphisms in patients with severe traumatic brain injury.
Sun Y et al.
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2017
Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y et al.
European Journal of Clinical Pharmacology, 2017
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Leong SL et al.
Scientific Reports, 2017
Pharmacogenetic Variation in Over 100 Genes in Patients Receiving Acenocumarol.
Gonzalez-Covarrubias V et al.
Frontiers in Pharmacology, 2017
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T et al.
Pharmacology & Therapeutics, 2016
UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.
Chatzistefanidis D et al.
Pharmacogenomics, 2016
Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.
Hu DG et al.
Drug Metabolism Reviews, 2016
Exome-Wide Association Study Identifies New Low-Frequency and Rare UGT1A1 Coding Variants and UGT1A6 Coding Variants Influencing Serum Bilirubin in Elderly Subjects: A Strobe Compliant Article.
Oussalah A et al.
Medicine, 2015
Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.
Scherer D et al.
Genes, Chromosomes & Cancer, 2014
Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.
Dadheech S et al.
Gene, 2013
S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Kim SY et al.
British Journal of Cancer, 2013
UGT1A6 polymorphisms modulated lung cancer risk in a Chinese population.
Kua LF et al.
Plos One, 2012
Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy.
Guo Y et al.
Drug Metabolism and Pharmacokinetics, 2012
Association of genetic variants in six candidate genes with valproic acid therapy optimization.
Hung CC et al.
Pharmacogenomics, 2011
Characterizing the effects of common UDP glucuronosyltransferase (UGT) 1A6 and UGT1A1 polymorphisms on cis- and trans-resveratrol glucuronidation.
Iwuchukwu OF et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling.
Xing Y et al.
Pharmacogenomics, 2009
Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants.
Benoit-Biancamano MO et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
Argikar UA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Genotyping panel for assessing response to cancer chemotherapy.
Dai Z et al.
Bmc Medical Genomics, 2008
UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P et al.
Journal of Chemotherapy (florence, Italy), 2008
Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population.
Yea SS et al.
Therapeutic Drug Monitoring, 2008
[Effect of UGT1A6 genetic polymorphisms on the metabolism of sodium valproate].
Sun YP et al.
Zhonghua Yi Xue Za Zhi, 2007
Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
Nagar S et al.
Oncogene, 2006
UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).
Krishnaswamy S et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation.
Krishnaswamy S et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
Genetic polymorphisms of UGT1A6 in a Japanese population.
Saeki M et al.
Drug Metabolism and Pharmacokinetics, 2005
Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells.
Nagar S et al.
Pharmacogenetics, 2004